April 15, 2008 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in the European Union covering its lead dermatology agent, PH-10, along with a number of related agents and their use. Provectus has also received allowance of another patent application in Canada covering applicator devices used with PH-10 and related agents. The pending patents cover topical products for treatment of skin diseases such as psoriasis and eczema, along with certain medical devices for application of PH-10 to internal surfaces of the body.
"Coming on the heels of our recent patents in the U.S. and India for PH-10, these pending patents from the European Patent Office (EPO) and the Canadian Intellectual Property Office are further milestones validating our efforts to obtain maximum right of ownership for products that may be sold in major markets worldwide," said Craig Dees, PhD, CEO of Provectus. "The EPO patent will also cover topical products based on PH-12, our novel photoactive analog of PH-10."
No comments:
Post a Comment